文献速递脊柱外科

腰椎融合术后酮咯酸给药与假关节形成:一项匹配队列研究

Postoperative Ketorolac Administration and Pseudoarthrosis Following Lumbar Spinal Fusion: A Matched Cohort Study.
PubMed 文献 · Spine (Phila Pa 1976) · 2025-08-19

这项回顾性队列研究利用TriNetX数据库,将腰椎融合术后使用酮咯酸的患者与未使用者按1:1匹配,每组15260例。酮咯酸组短期阿片类处方更少,深静脉血栓、肺栓塞和肠梗阻风险更低,未增加急性肾损伤、肌酐或输血率;1年和2年假关节形成率相当,机械并发症更少。作者认为酮咯酸可能是术后疼痛管理中的安全辅助用药,但需进一步随机试验。

要点

  • 匹配后每组15260例,酮咯酸组7天阿片类处方2.5 vs 2.8(P<0.001)。
  • 酮咯酸组深静脉血栓、肺栓塞和肠梗阻风险更低(P<0.05)。
  • 1年和2年假关节形成率相当,机械并发症更少。

核心结论

  • 术后酮咯酸可能减少短期阿片类使用和血栓栓塞风险,且不增加假关节形成或机械并发症。
  • 作者认为这些发现支持酮咯酸作为术后疼痛管理中可能安全的辅助用药。
  • 作者指出需进一步随机试验。

研究设计与样本

  • 回顾性队列研究,使用TriNetX数据库。
  • 纳入接受腰椎融合术且随访≥30天的患者,排除既往假关节形成者。
  • 按术后酮咯酸使用分组,按性别、年龄、族裔和合并症1:1匹配。
  • 匹配后每组15260例。

主要发现

  • 酮咯酸组所有短期时间点阿片类处方更少(如7天时2.5 vs 2.8,P<0.001),肠道方案使用更少(P<0.001)。
  • 酮咯酸组深静脉血栓、肺栓塞和肠梗阻风险更低(P<0.05)。
  • 未观察到急性肾损伤、肌酐或输血率增加。
  • 1年和2年时,酮咯酸使用者机械并发症减少,假关节形成率相当。

关键数值与推荐

  • 主要结局包括7、14和30天阿片类处方,以及1年和2年假关节形成。
  • 次要结局包括肠道方案使用、肠梗阻、深静脉血栓、肺栓塞、急性肾损伤、输血、感染、伤口裂开、实验室值(血红蛋白、血细胞比容、肌酐)、再入院、急诊就诊和1年及2年机械并发症。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: Retrospective cohort study. OBJECTIVE: To evaluate opioid utilization and pseudoarthrosis risk following lumbar spinal fusion in patients receiving postoperative ketorolac versus those who did not. BACKGROUND: Ketorolac is increasingly used in multimodal pain regimens to reduce opioid use. However, its effect on bone healing, particularly after lumbar fusion, remains unclear. MATERIALS AND METHODS: Using the TriNetX database, we identified patients undergoing lumbar spinal fusion with ≥30 days of follow-up, excluding those with prior pseudoarthrosis. Patients were grouped by postoperative ketorolac use and matched 1:1 by sex, age, ethnicity, and comorbidities. Primary outcomes included opioid prescriptions at 7, 14, and 30 days. Pseudoarthrosis was assessed at one and two years. Secondary outcomes included bowel regimen use, ileus, DVT, PE, AKI, transfusion, infection, wound disruption, lab values (Hgb, Hct, Cr), readmissions, ED visits, and mechanical complications at one and two years. RESULTS: After matching, 15,260 patients were included in each group. Ketorolac use was associated with fewer opioid prescriptions at all short-term timepoints ( e.g. 2.5 vs. 2.8 at 7 d, P <0.001) and less bowel regimen use ( P <0.001). DVT, PE, and ileus risk were lower in the ketorolac group ( P <0.05). No increase in AKI, Cr, or transfusion rates was observed. At one and two years, ketorolac users had reduced mechanical complications and comparable pseudoarthrosis rates. CONCLUSIONS: Postoperative ketorolac may reduce short-term opioid use and thromboembolic risk without increasing pseudoarthrosis or mechanical complications. These findings support ketorolac as a potentially safe adjunct in postoperative pain management. Further randomized trials are warranted.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Ogilvie D, Ogilvie B, Mysore A, et al. Postoperative Ketorolac Administration and Pseudoarthrosis Following Lumbar Spinal Fusion: A Matched Cohort Study. Spine (Phila Pa 1976). 2025. PMID: 40827608. doi:10.1097/BRS.0000000000005474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。